The STEAM-MAP 1 Study is a single-arm, prospective feasibility trial evaluating the integration of MRI-transrectal ultrasound (TRUS) fusion guidance into Rezūm water vapor thermal therapy for men with symptomatic benign prostatic hyperplasia (BPH).
Age 30-80 years old with symptomatic BPH.
Prostate volume 30-80 mL (TRUS/MRI/US)
Suitable for Rezum.
Able to consent and comply with follow-up to 1 month.
Known/suspected prostate cancer requiring oncologic management.
Prior prostate surgery impacting urethral anatomy within 12 months.
Prior implant affecting urethral anatomy.
Active UTI or untreated bacteriuria pre-op.